title: Current medical management of secondary hyperparathyroidism.
abstract: The treatment of secondary hyperparathyroidism (HPT) in patients with chronic renal disease has improved markedly in recent years. The skeletal pain, disabling fractures, tendon ruptures, and myriad other symptoms associated with HPT can now be avoided, and the quality of life of patients with end-stage renal disease is improved. Control of hyperphosphatemia, maintenance of normocalcemia, and appropriate dosing of vitamin D analogues can prevent HPT in many cases. Palatable, nutritious diets should be followed; serum calcium, phosphorus, alkaline phosphatase, and parathyroid hormone should be monitored; and treatment regimens should be adjusted accordingly. If prevention fails, and even if severe HPT develops, many of these patients can still be controlled medically with correction of hyperphosphatemia and high doses of intravenous calcitriol. In our experience, only a few patients require surgical parathyroidectomy (usually noncompliant patients or patients whose HPT has been poorly managed from early uremia). The essence to medical management is to correct the two most important pathogenetic factors of HPT, hyperphosphatemia, and calcitriol deficiency. We present the current approach to the management of HPT, with highlights of recent advances.
authors.affiliation: Department of Veteran Affairs Medical Center, East Orange, New Jersey, USA.
authors.forename: M
authors.initials: M
authors.lastname: Yudd
authors.forename: F
authors.initials: F
authors.lastname: Llach
mesh_terms: D000085:Acetates / Q000494:pharmacology; D000284:Administration, Oral; D002117:Calcitriol / Q000008:administration & dosage; D002118:Calcium / Q000097:blood; D002119:Calcium Carbonate / Q000494:pharmacology; D017610:Calcium Compounds; D000431:Ethanol / Q000008:administration & dosage; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000150:complications / Q000628:therapy*; D007275:Injections, Intravenous; D007408:Intestinal Absorption / Q000187:drug effects; D007676:Kidney Failure, Chronic / Q000150:complications; D017616:Magnesium Compounds / Q000494:pharmacology; D010281:Parathyroid Hormone / Q000097:blood; D016105:Parathyroidectomy; D010710:Phosphates / Q000097:blood; D016226:Phosphorus, Dietary / Q000097:blood
chemical_list: D000085:Acetates; D017610:Calcium Compounds; D017616:Magnesium Compounds; D010281:Parathyroid Hormone; D010710:Phosphates; D016226:Phosphorus, Dietary; D000431:Ethanol; D002117:Calcitriol; D002119:Calcium Carbonate; D002118:Calcium; C120662:calcium acetate